Non revenue generating Biotech is getting pummelled. I think IMM has held up pretty well. This stock still feels like a Punt stock to me, evidenced by the fact that no single shareholder holds more than about 1.8%. One of those Asymmetric payoff profiles.
I like it as a punt, but the market is penalising this sector severely. Good thing they have some cash to see them through a couple of years.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72820 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 49499 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |